<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522570</url>
  </required_header>
  <id_info>
    <org_study_id>1255/18</org_study_id>
    <nct_id>NCT04522570</nct_id>
  </id_info>
  <brief_title>Thermal Ablation of Cervical Metastases From Thyroid Carcinoma</brief_title>
  <official_title>Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical response and safety of ultrasound guided percutaneous&#xD;
      thermal ablation of lymph node metastases from thyroid carcinoma as an alternative to&#xD;
      surgical treatment.&#xD;
&#xD;
      The ablation of cervical lymph node metastases from differentiated thyroid carcinoma or&#xD;
      medullary thyroid carcinoma will be directed to lesions larger than 0.8 cm, using&#xD;
      ultrasound-guided radiofrequency ablation (RFA), laser ablation (LA) or cryoablation (Cryo)&#xD;
      techniques, randomly assigned. Clinical and ultrasound monitoring will be carried out during&#xD;
      24 months, with examinations before the ablation procedure, immediately after including&#xD;
      contrast-enhanced ultrasound (CEUS) when applicable, and B-mode, color Doppler and Shear-Wave&#xD;
      elastography ultrasound follow up with 6, 12, and 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroidectomy is the main treatment of well differentiated thyroid carcinoma. Residual or&#xD;
      recurrent cervical metastases are common (9-20% of patients during long-term follow up).&#xD;
      Thermal ablation of cervical metastatic lymph nodes from thyroid carcinoma has been proposed&#xD;
      in research centers as an option for the treatment of patients who remain with metastatic&#xD;
      disease in cervical lymph nodes, despite thyroidectomy with or without neck dissection&#xD;
      associated with radioiodine treatment. Potential advantages from percutaneous thermal&#xD;
      ablation are related to less complication rates, less morbidity, possibility of outpatient&#xD;
      treatment modality, and less global treatment costs when compared to the surgical approach.&#xD;
&#xD;
      Aims of the study:&#xD;
&#xD;
        1. To evaluate safety and efficacy of ultrasound-guided thermal ablation in the treatment&#xD;
           of cervical lymph node metastases from differentiated thyroid carcinoma&#xD;
&#xD;
        2. To evaluate the best response to thermal ablation defined as lymph node reduction or&#xD;
           volume stability after ablation&#xD;
&#xD;
        3. To evaluate the CEUS patterns of lymph nodes before and after ablation&#xD;
&#xD;
        4. To evaluate the elastography patterns of lymph nodes before and after ablation&#xD;
&#xD;
        5. To evaluate the tumor marker response after ablation&#xD;
&#xD;
        6. To evaluate the contribution of thermal ablation to decrease additional therapeutic&#xD;
           procedures&#xD;
&#xD;
        7. To compare differences between LA, RFA and cryoablation in terms of complications, side&#xD;
           effects and tolerability&#xD;
&#xD;
      Patients with cervical metastatic lymph nodes from differentiated thyroid carcinoma or&#xD;
      medullary thyroid carcinoma who meet the eligibility criteria and who have been determined to&#xD;
      be an appropriate candidate for local ablation therapy will be offered enrollment into the&#xD;
      study. Patients agreeing to participate will become subjects of the study if they read and&#xD;
      sign an informed consent form.&#xD;
&#xD;
      Treatment will be performed using three different ablation technologies (laser ablation, RFA&#xD;
      or cryoablation) in a randomly assignment fashion.&#xD;
&#xD;
      Subjects will have up to six simultaneous treated lesions larger than 0.8 cm diameter with&#xD;
      positive fine-needle aspiration biopsy. Ultrasound (and CEUS when applicable) will be&#xD;
      performed over 24 months follow up in order to evaluate efficacy. Baseline and follow-up data&#xD;
      will be collected for each subject via a web-based electronic data collection tool.&#xD;
&#xD;
      In case of recurrent disease treated by any ablative technique in patients who did not&#xD;
      undergo previous neck dissection, a rescue neck dissection will be performed; in case of&#xD;
      recurrent disease treated by any ablative technique in patients who underwent previous neck&#xD;
      dissection, a new ablative technique approach will be considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of technical feasibility</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>defined as the ability to target the nodule and to perform ablation as preoperatively planned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of thermal ablation of thyroid carcinoma cervical lymph node metastases</measure>
    <time_frame>up to 4 weeks post-ablation</time_frame>
    <description>Evaluation of minor and major complication rates, immediately after ablation; and one- and four-weeks post-ablation by telephone call.&#xD;
Minor and major complication rates [Designed as a safety issue: Yes]. The safety endpoint for this study is to assess the incidence and severity of procedure or device-related adverse events, as reported by the Common Terminology Criteria of Adverse Events - CTCAE V5. 2017 Version.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of technical success</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>Defined as the complete absence of color Doppler or, if applicable when tumors over 1.0 cm diameter, enhancement by contrast-enhanced ultrasound in the treated nodule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of contrast-enhanced ultrasound pattern after thermal ablation therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Absence of enhancement is expected in treated cervical lymph nodes after local ablative therapy in comparison to pre-treatment enhancement pattern. Partial enhancement may indicate residual tumoral tissue requiring new ablation session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of elastography pattern after thermal ablation therapy</measure>
    <time_frame>24 months</time_frame>
    <description>Quantitative measurements of nodule stiffness designated by the most representative region of interest within the nodule estimating of Young's modulus in kilopascal (KPa) and shear wave velocity in centimetres per second (cm/s) of treated cervical lymph nodes after local ablative therapy in comparison to pre-treatment pattern.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response to the thermal ablation therapy</measure>
    <time_frame>24 months</time_frame>
    <description>The best response is defined as a subject having local disease control related to lymph node volume reduction or volume stability in percentage will be assessed by ultrasound measurement in comparison to pre-treatment volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tumor marker response</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with tumor marker response: defined in negative thyroglobulin, calcitonin, or carcinoembryonic antigen (CEA) levels or anti-thyroglobulin antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of additional therapies</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with additional therapies: Additional therapies for persistent/recurrent local disease associated with the index tumor (s) under study or new cervical lymph node metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes among thermal ablation therapies</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with complications, side effects and tolerability in each ablation technique.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thyroid Neoplasia</condition>
  <condition>Well-Differentiated Thyroid Cancer</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>laser ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous Laser Ablation for the treatment of metastatic cervical lymph nodes with &gt; 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cryoablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous cryoablation for the treatment of metastatic cervical lymph nodes with &gt; 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous radio frequency ablation for the treatment of metastatic cervical lymph nodes with &gt; 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser ablation</intervention_name>
    <description>Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;</description>
    <arm_group_label>laser ablation</arm_group_label>
    <other_name>LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;</description>
    <arm_group_label>cryoablation</arm_group_label>
    <other_name>Cryo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Patients with fine needle aspiration biopsy (FNAb)-proven metastatic cervical lymph&#xD;
             nodes at levels I, II, III, IV, V, VI or VII from differentiated thyroid carcinoma or&#xD;
             medullary thyroid carcinoma who underwent total thyroidectomy and subsequent&#xD;
             radioiodine therapy, in case of differentiated thyroid carcinoma.&#xD;
&#xD;
          -  Patients considered high surgical risk candidate or patients who are informed about&#xD;
             the ablation therapy and prefers it instead surgery;&#xD;
&#xD;
          -  Patients with metastatic cervical lymph nodes over 0.8 cm diameter and under 4.0 cm&#xD;
             diameter; no more than 6 simultaneous cervical nodal metastases;&#xD;
&#xD;
          -  Cervical recurrences in previously lateral neck dissection patients for differentiated&#xD;
             thyroid carcinoma or medullary thyroid carcinoma over 0.8 cm diameter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Uncorrectable coagulopathy;&#xD;
&#xD;
          -  Inconclusive or benign cytologic specimens;&#xD;
&#xD;
          -  Pregnancy or breast-feeding;&#xD;
&#xD;
          -  Anaplastic or poor-differentiated thyroid carcinoma;&#xD;
&#xD;
          -  Partial thyroidectomy&#xD;
&#xD;
          -  Cervical tumors not considered to surgery (invading vessels, nerves, larynx or&#xD;
             trachea);&#xD;
&#xD;
          -  Serious medical illness, including any of the following: uncontrolled angina,&#xD;
             myocardial infarction, cerebrovascular event within 6 months prior to the baseline&#xD;
             visit, uncontrolled congestive heart failure;&#xD;
&#xD;
          -  Participation in other studies that could affect the primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo MC Freitas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo MC Freitas, PhD</last_name>
    <phone>551138932945</phone>
    <email>ricardo.freitas@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana O Hoff, PhD</last_name>
    <phone>551138932945</phone>
    <email>ana.hoff@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talita R Vincunas</last_name>
      <phone>551138932945</phone>
      <email>talita.vincunas@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo MC Freitas, PhD</last_name>
      <phone>551138932945</phone>
      <email>ricardo.freitas@hc.fm.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Ricardo MC Freitas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana O Hoff, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco AV Kulcsar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Hong YR, Luo ZY, Mo GQ, Wang P, Ye Q, Huang PT. Role of Contrast-Enhanced Ultrasound in the Pre-operative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma. Ultrasound Med Biol. 2017 Nov;43(11):2567-2575. doi: 10.1016/j.ultrasmedbio.2017.07.010. Epub 2017 Aug 12.</citation>
    <PMID>28807450</PMID>
  </reference>
  <reference>
    <citation>Guenette JP, Tuncali K, Himes N, Shyn PB, Lee TC. Percutaneous Image-Guided Cryoablation of Head and Neck Tumors for Local Control, Preservation of Functional Status, and Pain Relief. AJR Am J Roentgenol. 2017 Feb;208(2):453-458. doi: 10.2214/AJR.16.16446. Epub 2016 Nov 15.</citation>
    <PMID>27845860</PMID>
  </reference>
  <reference>
    <citation>Guang Y, Luo Y, Zhang Y, Zhang M, Li N, Zhang Y, Tang J. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. J Cancer Res Clin Oncol. 2017 Aug;143(8):1555-1562. doi: 10.1007/s00432-017-2386-6. Epub 2017 Mar 24.</citation>
    <PMID>28342000</PMID>
  </reference>
  <reference>
    <citation>Wang L, Ge M, Xu D, Chen L, Qian C, Shi K, Liu J, Chen Y. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma. J Cancer Res Ther. 2014 Nov;10 Suppl:C144-9. doi: 10.4103/0973-1482.145844.</citation>
    <PMID>25450273</PMID>
  </reference>
  <reference>
    <citation>Mauri G, Cova L, Ierace T, Baroli A, Di Mauro E, Pacella CM, Goldberg SN, Solbiati L. Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. Cardiovasc Intervent Radiol. 2016 Jul;39(7):1023-30. doi: 10.1007/s00270-016-1313-6. Epub 2016 Feb 24.</citation>
    <PMID>26911732</PMID>
  </reference>
  <reference>
    <citation>Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, Salvatori M, Solbiati L, Crescenzi A, Pacella CM, Gharib H. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab. 2013 Jan;98(1):E92-7. doi: 10.1210/jc.2012-2991. Epub 2012 Nov 12.</citation>
    <PMID>23150695</PMID>
  </reference>
  <reference>
    <citation>Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007 Feb;8(2):148-56. Review.</citation>
    <PMID>17267329</PMID>
  </reference>
  <reference>
    <citation>Monaco F. Classification of thyroid diseases: suggestions for a revision. J Clin Endocrinol Metab. 2003 Apr;88(4):1428-32. Review.</citation>
    <PMID>12679417</PMID>
  </reference>
  <reference>
    <citation>Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med. 2004 Oct 21;351(17):1764-71. Review.</citation>
    <PMID>15496625</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>differentiated thyroid cancer</keyword>
  <keyword>medullary thyroid cancer</keyword>
  <keyword>cervical lymph nodes</keyword>
  <keyword>contrast-enhanced ultrasound</keyword>
  <keyword>thermal ablation</keyword>
  <keyword>laser ablation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>cryoablation</keyword>
  <keyword>elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available within 18 months of study completion and for 6 months.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

